News | Ventricular Assist Devices (VAD) | June 11, 2015

ECRI Institute Review Supports Impella RP Device

Overview of published articles indicates significant improvement in hemodynamics with high short- and long-term survival rates

ECRI Institute, review, Impella RP, Abiomed

June 11, 2015 - ECRI Institute recently reviewed published data on Abiomed's Impella RP (Right Percutaneous) transcatheter ventricular assist device (VAD). The institute said the device provides immediate significant improvements in hemodynamics with considerable short-term and long-term survival rates.

The Impella RP is a catheter-based intracardiac microaxial blood pump to support short-term pulmonary circulation in pediatric or adult patients. It is intended to provide percutaneous circulatory support to restore normal right heart hemodynamics, reduce right ventricular work, and enable the right heart to potentially recover or sustain the patient until the next therapy.

ECRI searched PubMed, EMBASE and selected Web-based resources for relevant documents published between Jan. 1, 2010, and April 30, 2015. The healthcare technology research firm identified two small nonrandomized comparison studies and three small cohort studies (two of which were retrospective) reporting on 138 patients.

Review of the abstracts of published articles suggests that Impella RP provides immediate significant improvements in hemodynamics with short-term (30 days) and long-term (1 year) survival rates of approximately 70 and 50 percent, respectively. Study populations were small and consisted of mostly male adults with acute right heart failure. Only one study reported on adverse events.

ECRI was unable to determine whether Impella RP works better than similar right ventricular assist devices (e.g., Excor Pediatric VAD, Percutaneous ventricular assist device [PVAD]/implantable ventricular assist device [IVAD] or CentriMag right ventricular assist device [RVAD]) because no studies were available that compare the devices.

The ECRI Institute is an independent nonprofit organization that conducts research into the most effective approaches for improving patient care.  

For more information: www.ecri.org

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Overlay Init